Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355,
evaluating the combination of Keytruda (pembrolizumab) and chemo in
patients with metastatic triple-negative breast cancer (TNBC) whose
tumors express PD-L1 (Combined Positive Score at least 10) met one of
the dual primary endpoints, progression-free survival (PFS).
In a first-line setting, treatment with the
Keytruda combo resulted in a statistically significant increase in PFS
compared to chemo alone.
The trial will continue unchanged in order to assess the other primary endpoint of overall survival (OS).
Detailed data will be submitted for presentation at a future medical conference and reviewed with regulatory authorities.
https://seekingalpha.com/news/3540935-mercks-keytruda-meets-pfs-endpoint-in-tnbc-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.